Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.45 USD
Change Today +0.401 / 13.15%
Volume 12.2M
As of 11:41 AM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

geron corp (GERN) Key Developments

Geron Corporation Mulls Acquisitions

Geron Corporation (NasdaqGS:GERN) is seeking acquisitions. Geron Corporation has filed a follow-on equity offering in the amount of $50.00 million. Geron Corporation will use the net proceeds from the sale of the securities under this prospectus, if any, for working capital and general corporate purposes, which may include funding research and development, general and administrative activities and capital expenditures, as well to potentially in-license or acquire other oncology products, programs or companies to diversify our business.

Geron Corporation Announces Consolidated Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Geron Corporation announced consolidated unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported license fees and royalties revenue of $251,000 compared with $341,000 for the same period a year ago. Loss from operations was $9,479,000 compared with $8,663,000 for the same period a year ago. Net loss was $9,356,000 or $0.06 per basic and diluted share compared with $8,734,000 or $0.06 per basic and diluted share for the same period a year ago. For the six months, the company reported license fees and royalties revenue of $788,000 compared with $815,000 for the same period a year ago. Loss from operations was $18,935,000 compared with $17,394,000 for the same period a year ago. Net loss was $18,671,000 or $0.12 per basic and diluted share compared with $17,174,000 or $0.11 per basic and diluted share for the same period a year ago.

Geron Mulls Acquisitions

Geron Corporation (NasdaqGS:GERN) intends to pursue acquisitions. "Our business development efforts continue, as we seek to identify and acquire and/or in-license other oncology products, programs or companies," said John A. Scarlett, Geron's President and Chief Executive Officer.

Geron Corporation Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Geron Corporation reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported loss from operations of $9,456,000, net loss of $9,315,000 or $0.06 loss per share on license fees and royalties of $537,000 against loss from operations of $8,731,000, net loss of $8,440,000 or $0.06 loss per share on license fees and royalties of $474,000 for the same period a year ago. The increase in interest and other income in 2015 compared to 2014 was due to higher cash and investment balances in 2015.

Geron Corporation Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 03:40 PM

Geron Corporation Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 03:40 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: John A. Scarlett, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GERN:US $3.46 USD +0.409

GERN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioTime Inc $3.03 USD -0.08
Neuralstem Inc $1.51 USD -0.01
Ocata Therapeutics Inc $4.61 USD -0.24
ReNeuron Group PLC 5.25 GBp 0.00
StemCells Inc $0.54 USD +0.071
View Industry Companies
 

Industry Analysis

GERN

Industry Average

Valuation GERN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 411.3x
Price/Book 3.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 288.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GERON CORP, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.